Skip to main content

Advertisement

Table 2 Baseline characteristics of patients with prostate cancer according to Ki67 CTC status

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

Characteristic Ki67 CTC-negative patients (no Ki67 + ve CTCs) (%) Ki67 CTC-positive patients (≥1 Ki67 + ve CTC) (%)
Total patient numbers 28 23
Age, years
 Median 79.5 72
 Range 63–90 52–89
Number of metastasic sites
 1 12/28 (42.9) 8/23 (34.8)
 2 10/28 (35.7) 8/23 (34.8)
 3+ 4/28 (14.3) 7/23 (30.4)
 Not stated 2/28 (7.1) 0/23 (0)
Metastasic sites   
 Lymph Nodes alone 0/28 (0) 0/23 (0)
 Bone alone 12/28 (42.9) 8/23 (34.8)
 Bone and lymph nodes 8/28 (28.6) 5/23 (21.7)
 Visceral/multiple sites 6/28 (21.4) 10/23 (43.5)
 Unknown/Not stated 2/28 (7.1) 0/23 (0)
Treatment at time of 1st CTC specimen
 Cabazitaxel 0/28 (0) 6/23 (23.1)
 Docetaxel 6/28 (21.4) 3/23 (13)
 Abiraterone 13/28 (46.4) 11/23 (47.8)
 Others/Not stated 9/28 (32.1) 3/23 (13)
Line of treatment at time of 1st CTC specimen
 1 5/28 (17.9) 3/23 (13)
 2 8/28 (28.6) 5/23 (21.7)
 3+ 3/28 (10.7) 7/23 (30.4)
 Not stated 12/28 (42.9) 8/23 (34.8)
Previous treatments
 Primary surgery 5/28 (17.9) 3/23 (13)
 Primary radiotherapy 6/28 (21.4) 5/23 (21.7)
 Docetaxel 21/28 (75) 20/23 (87)
 Enzalutamide 1/28 (3.6) 0/23 (0)
 Cabazitaxel 1/28 (3.6) 0/23 (0)
 Abiraterone 2/28 (7.1) 5/23 (21.7)
Total CTC levels at baseline
 Mean 12.9 92.8
 Range 0–79 2–316